|
|
|
|
|
|
Marketed Product Acquisition: Our client was in the process of transforming from an R&D company into a commercial organization in the cancer field when an
attractive supportive care product became available as a result of a large company merger. We helped our client through two rounds of bids for the product, conducting due
diligence, preparing valuation models, projecting the implications for the base business and infrastructure requirements, and developing the bid.
In-licensing Due Diligence: The business development team at a large pharmaceutical client engaged Health Advances to prepare a rapid turn around due diligence
of a novel infectious disease product which they were considering licensing from a third party. Several other bidders were in the field; it was a novel approach to disease
management and there was one major competitive threat. Our analysis recommended a valuation range.
Deal Strategy and Due Diligence: Health Advances conducted an extended acquisition-focused project with a small public biotech company seeking to complete a
major acquisition. Over a period of several months, and in parallel with due-diligence level review of several possible candidates, Health Advances advised the management
team on the criteria that it should use for evaluating the attractiveness and strategic fit. Health Advances continued to assist in the due diligence of various candidates
that met those criteria until a deal was completed.
European Acquisition Candidate Search and Evaluation: Health Advances screened and reviewed OTC product and company acquisition opportunities in Europe for
a major public pharmaceutical company. The project involved creating a database for capturing quantitative and qualitative information on a wide range of products and
company product lines. Health Advances developed a set of criteria for screening the compounds, including such attributes as segment size and growth, product share and growth,
competitive characteristics of the segment, fit with the client's skill sets and potential availability.
|
|
 |
|
|
|
|
